Nine Big Pharma to cut US drug prices in Most-favoured Nations deals

Following Pfizer, AstraZeneca, Merck KGaA, Eli Lilly and Novo Nordisk, nine more pharma giants  will reduce US drug prices under Most-Favoured-Nation agreements. Discounts up to 90 % for drugs from Amgen, BMS, Gilead, GSK, Merck & Co, Novartis, Genentech (Roche) and Sanofi will be offered via TrumpRx and direct-to-patient (DTC) channels.

In exchange for these price reductions, the companies will be allowed to import externally manufactured products duty-free for three years, provided they establish new production facilities in the US. Without these investments, the tariff exemptions will not apply.

From 1 January 2026, Amgen will expand its direct-to-patient programme AmgenNow™. The migraine drug Aimovig will be offered at around 60 % discount, and the Humira biosimilar Amjevita will be available at roughly 80 % off. Repatha (Evolocumab) will also become more affordable through the same channels. Bristol Myers Squibb will provide its anticoagulant Eliquis for free via Medicaid and will supply large amounts of the active pharmaceutical ingredient to secure the supply chain. Other medicines such as Reyataz, Sotyktu, Baraclude and Zeposia will also be available at reduced prices.

Boehringer Ingelheim will offer the diabetes medicine Jentadueto via direct channels at a 90 % discount, while Genentech will make the flu drug Xofluza available at approximately 70 % off via TrumpRx. Gilead Sciences will provide Epclusa for hepatitis C at around 90 % discount, alongside other HIV and COVID-19 treatments at reduced prices. GSK will offer inhaled therapies for respiratory conditions, such as Advair Diskus, at up to 66 % discount through direct programmes.

Merck & Co. will supply its diabetes drugs Januvia, Janumet and Janumet XR via direct programmes at roughly 70 % discount. Future products, including the experimental LDL-lowering drug enlicitide, will follow once approved. Novartis will make its multiple sclerosis drug Mayzent and the cancer treatments Rydapt and Tabrecta available via TrumpRx at discounts of up to 89 %. Sanofi will provide insulin and various diabetes, cardiovascular and neurological medicines at an average 61 % discount, also accessible through TrumpRx.

The agreements will restructure the US pharmaceutical market. Bestsellers such as Aimovig, Eliquis, Epclusa and Januvia will become significantly more affordable for patients, with discounts ranging from 60% to 90% through direct channels and Medicaid. Analysts welcomed the improved transparency and patient access but warn that practical outcomes may vary. The US MFN policy has triggered price hikes in other markets.